Coya Therapeutics to Present Innovative Treg Strategies at Evercore HealthCONx Conference 2024

Coya Therapeutics to Showcase Innovative Treg Approach at Evercore HealthCONx Conference

Coya Therapeutics, Inc., a Houston-based clinical-stage biotechnology company, prepares to highlight its groundbreaking work in enhancing regulatory T cell (Treg) function at the upcoming 7th Annual Evercore HealthCONx Conference, scheduled for December 3 to 5, 2024. The company’s CEO Dr. Arun Swaminathan and Executive Chairman Dr. Howard Berman will participate in a fireside chat on December 3, moderated by Michael DiFiore from Evercore ISI. This forum offers a unique opportunity for Coya to engage with investors and industry peers, demonstrating its commitment to addressing systemic and neuroinflammation through innovative therapies.

Coya Therapeutics focuses on targeting dysfunctional Tregs, which are implicated in a variety of conditions characterized by chronic inflammation and immune dysregulation, including neurodegenerative, metabolic, and autoimmune diseases. The company’s product pipeline features a range of Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, all aimed at restoring immune balance. Notably, Coya's lead investigational product, COYA 302, combines a low-dose IL-2 (COYA 301) with CTLA4-Ig for subcutaneous administration. This unique dual mechanism of action is designed to treat conditions such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease.

The therapeutic potential of COYA 302 is significant, as it seeks to enhance Treg numbers and functions while simultaneously reducing the activity of microglia and the secretion of pro-inflammatory mediators. Such a multi-targeted approach allows for a more effective restoration of immune balance, which could lead to better outcomes compared to existing therapies that utilize low-dose IL-2 or CTLA4-Ig in isolation. Coya’s participation in the conference underscores its mission to advance novel treatment strategies that address the underlying causes of debilitating diseases, promoting a new understanding of immune regulation in the process.

In addition to the fireside chat, Coya Therapeutics will offer opportunities for one-on-one meetings throughout the conference, allowing stakeholders to engage directly with the leadership team. For those unable to attend, Coya plans to provide an archived webcast of the presentation on its website, ensuring access to the insights shared during this important event. This initiative reflects the company’s dedication to transparency and communication with its stakeholders as it navigates the complexities of biotechnology innovation.